Spots Global Cancer Trial Database for indium in 111 ibritumomab tiuxetan
Every month we try and update this database with for indium in 111 ibritumomab tiuxetan cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | NCT00088881 | Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... WaldenstrĂśm Mac... | rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00005592 | Lymphoma | 90-Y-ibritumoma... rituximab indium In 111 i... | 18 Years - | University of Alabama at Birmingham | |
| Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | NCT00012298 | Extranodal Marg... Nodal Marginal ... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Margi... Recurrent Small... Splenic Margina... WaldenstrĂśm Mac... | rituximab yttrium Y 90 ib... indium In 111 i... oprelvekin filgrastim | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma | NCT00058422 | Lymphoma | darbepoetin alf... filgrastim rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... indium In 111 i... yttrium Y 90 ib... | 60 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | NCT00577278 | Graft Versus Ho... Leukemia Lymphoma | rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom... | 18 Years - 69 Years | City of Hope Medical Center | |
| Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder | NCT00064246 | Post-transplant... Recurrent Adult... Recurrent Adult... Stage III Adult... Stage III Adult... Stage IV Adult ... Stage IV Adult ... WaldenstrĂśm Mac... | rituximab indium In 111 i... yttrium Y 90 ib... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | NCT00088881 | Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... WaldenstrĂśm Mac... | rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | NCT00088881 | Contiguous Stag... Extranodal Marg... Nodal Marginal ... Noncontiguous S... Splenic Margina... Stage I Adult D... Testicular Lymp... WaldenstrĂśm Mac... | rituximab prednisone cyclophosphamid... doxorubicin vincristine indium In 111 i... radiation thera... positron emissi... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
